Regulation of immune responses by prostaglandin E 2

Journal of Immunology

Volumn 188, Issue 1, 2012, Pages 21-28

  Kalinski, Pawel ^a,b,c,d  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; AUTACOID; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR3; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; CYCLOOXYGENASE 2; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; RANTES;

CELL ACTIVATION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EFFECTOR CELL; ENZYME DEGRADATION; ENZYME SYNTHESIS; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATORY CELL; MACROPHAGE FUNCTION; MEMORY T LYMPHOCYTE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SHORT SURVEY; SUPPRESSOR CELL; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL;

ANIMALS; AUTOIMMUNE DISEASES; CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINES; CYCLOOXYGENASE 2; DENDRITIC CELLS; DINOPROSTONE; HUMANS; IMMUNOLOGIC MEMORY; INFLAMMATION MEDIATORS; KILLER CELLS, NATURAL; NEOPLASMS;

EID: 84855361145     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1101029     Document Type: Short Survey

References (129)

1. Phipps, R. P., S. H. Stein, and R. L. Roper. 1991. A new view of prostaglandin E regulation of the immune response. Immunol. Today 12: 349-352.
2. 2 via the isoprostane pathway: a mechanism for the generation of bioactive prostaglandins independent of cyclooxygenase. J. Biol. Chem. 278: 28479-28489.
3. Tai, H. H., C. M. Ensor, M. Tong, H. Zhou, and F. Yan. 2002. Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat. 68-69: 483-493. (Pubitemid 35247416)
4. Hata, A. N., and R. M. Breyer. 2004. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol. Ther. 103: 147-166. (Pubitemid 39209041)
5. 2 regulation of hematopoiesis and hematopoietic stem cell engraftment. Curr. Opin. Hematol. 17: 308-312.
6. Nagamatsu, T., and D. J. Schust. 2010. The immunomodulatory roles of macrophages at the maternal-fetal interface. Reprod. Sci. 17: 209-218.
7. Rivest, S. 2010. Interactions between the immune and neuroendocrine systems. Prog. Brain Res. 181: 43-53.
8. Yuhki, K., H. Kashiwagi, F. Kojima, J. Kawabe, and F. Ushikubi. 2010. Roles of prostanoids in the pathogenesis of cardiovascular diseases. Int. Angiol. 29(Suppl.): 19-27.
9. Yang, H., and C. Chen. 2008. Cyclooxygenase-2 in synaptic signaling. Curr. Pharm. Des. 14: 1443-1451. (Pubitemid 351993045)
10. 2 stimulates IL-8 gene expression in human colonic epithelial cells by a posttranscriptional mechanism. J. Immunol. 161: 3746-3752.
11. 2 promotes degranulation-independent release of MCP-1 from mast cells. J. Leukoc. Biol. 79: 95-104.
12. Wang, X. S., and H. Y. Lau. 2006. Prostaglandin E potentiates the immunologically stimulated histamine release from human peripheral blood-derived mast cells through EP1/EP3 receptors. Allergy 61: 503-506. (Pubitemid 43334121)
13. Weller, C. L., S. J. Collington, A. Hartnell, D. M. Conroy, T. Kaise, J. E. Barker, M. S. Wilson, G. W. Taylor, P. J. Jose, and T. J. Williams. 2007. Chemotactic action of prostaglandin E2 on mouse mast cells acting via the PGE2 receptor 3. Proc. Natl. Acad. Sci. USA 104: 11712-11717. (Pubitemid 47175078)
14. Wang, M. T., K. V. Honn, and D. Nie. 2007. Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev. 26: 525-534. (Pubitemid 350115125)
15. Harris, S. G., J. Padilla, L. Koumas, D. Ray, and R. P. Phipps. 2002. Prostaglandins as modulators of immunity. Trends Immunol. 23: 144-150. (Pubitemid 34178297)
16. 2. Trends Pharmacol. Sci. 20: 162-170.
17. 2 synthases. Clin. Immunol. 119: 229-240.
18. 2. Prostaglandins 19: 917-931.
19. 2. J. Pharm. Pharmacol. 35: 724-728.
20. Backlund, M. G., J. R. Mann, V. R. Holla, F. G. Buchanan, H. H. Tai, E. S. Musiek, G. L. Milne, S. Katkuri, and R. N. DuBois. 2005. 15- Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J. Biol. Chem. 280: 3217-3223. (Pubitemid 40223783)
21. Hirsch, F. R., and S. M. Lippman. 2005. Advances in the biology of lung cancer chemoprevention. J. Clin. Oncol. 23: 3186-3197. (Pubitemid 46211343)
22. Tseng-Rogenski, S., J. Gee, K. W. Ignatoski, L. P. Kunju, A. Bucheit, H. J. Kintner, D. Morris, C. Tallman, J. Evron, C. G. Wood, et al. 2010. Loss of 15-hydroxyprostaglandin dehydrogenase expression contributes to bladder cancer progression. Am. J. Pathol. 176: 1462-1468.
23. Eruslanov, E., S. Kaliberov, I. Daurkin, L. Kaliberova, D. Buchsbaum, J. Vieweg, and S. Kusmartsev. 2009. Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer. J. Immunol. 182: 7548-7557.
24. Yan, M., S. J. Myung, S. P. Fink, E. Lawrence, J. Lutterbaugh, P. Yang, X. Zhou, D. Liu, R. M. Rerko, J. Willis, et al. 2009. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc. Natl. Acad. Sci. USA 106: 9409-9413.
25. Judson, B. L., A. Miyaki, V. D. Kekatpure, B. Du, P. Gilleaudeau, M. Sullivan- Whalen, A. Mohebati, S. Nair, J. O. Boyle, R. D. Granstein, et al. 2010. UV radiation inhibits 15-hydroxyprostaglandin dehydrogenase levels in human skin: evidence of transcriptional suppression. Cancer Prev. Res. (Phila.) 3: 1104-1111.
26. 2. FASEB J. 25: 2408-2417.
27. Honda, A., Y. Sugimoto, T. Namba, A. Watabe, A. Irie, M. Negishi, S. Narumiya, and A. Ichikawa. 1993. Cloning and expression of a cDNA for mouse prostaglandin E receptor EP2 subtype. J. Biol. Chem. 268: 7759-7762. (Pubitemid 23120347)
28. Regan, J. W., T. J. Bailey, D. J. Pepperl, K. L. Pierce, A. M. Bogardus, J. E. Donello, C. E. Fairbairn, K. M. Kedzie, D. F. Woodward, and D. W. Gil. 1994. Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. Mol. Pharmacol. 46: 213-220. (Pubitemid 24271416)
29. Fujino, H., S. Salvi, and J. W. Regan. 2005. Differential regulation of phosphorylation of the cAMP response element-binding protein after activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. Mol. Pharmacol. 68: 251-259. (Pubitemid 41002965)
30. Nishigaki, N., M. Negishi, and A. Ichikawa. 1996. Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist. Mol. Pharmacol. 50: 1031-1037. (Pubitemid 26347726)
31. 2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J. Biol. Chem. 278: 12151-12156.
32. Fujino, H., K. A. West, and J. W. Regan. 2002. Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. J. Biol. Chem. 277: 2614-2619. (Pubitemid 34953286)
33. Sugimoto, Y., T. Namba, A. Honda, Y. Hayashi, M. Negishi, A. Ichikawa, and S. Narumiya. 1992. Cloning and expression of a cDNA for mouse prostaglandin E receptor EP3 subtype. J. Biol. Chem. 267: 6463-6466.
34. 2 resistance in fibrotic fibroblasts from humans and mice. Am. J. Pathol. 177: 2245-2255.
35. Goto, T., R. B. Herberman, A. Maluish, and D. M. Strong. 1983. Cyclic AMP as a mediator of prostaglandin E-induced suppression of human natural killer cell activity. J. Immunol. 130: 1350-1355. (Pubitemid 13159880)
36. Bankhurst, A. D. 1982. The modulation of human natural killer cell activity by prostaglandins. J. Clin. Lab. Immunol. 7: 85-91. (Pubitemid 12190707)
37. 2 is a potent regulator of interleukin-12- and interleukin-18-induced natural killer cell interferon-γ synthesis. Immunology 111: 298-305.
38. 2 suppressed IL-15-mediated human NK cell function through down-regulation of common γ-chain. J. Immunol. 166: 885-891.
39. + NK helper cells. J. Exp. Med. 202: 941-953.
40. 2 suppresses NK activity in vivo and promotes postoperative tumor metastasis in rats. Ann. Surg. Oncol. 10: 469-479.
41. Smith, R. J. 1977. Modulation of phagocytosis by and lysosomal enzyme secretion from guinea-pig neutrophils: effect of nonsteroid anti-inflammatory agents and prostaglindins. J. Pharmacol. Exp. Ther. 200: 647-657. (Pubitemid 8089855)
42. 2 overproduction in impaired pulmonary host response following bone marrow transplantation. J. Immunol. 177: 5499-5508.
43. 2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptormediated increase in intracellular cyclic AMP. J. Immunol. 173: 559-565.
44. 2 in alveolar macrophages. J. Immunol. 179: 8350-8356.
45. Serezani, C. H., J. Chung, M. N. Ballinger, B. B. Moore, D. M. Aronoff, and M. Peters-Golden. 2007. Prostaglandin E2 suppresses bacterial killing in alveolar macrophages by inhibiting NADPH oxidase. Am. J. Respir. Cell Mol. Biol. 37: 562-570. (Pubitemid 350058187)
46. 2-induced immunosuppression post-bone marrow transplantation. J. Immunol. 184: 6299-6308.
47. Hu, Z. Q., K. Asano, H. Seki, and T. Shimamura. 1995. An essential role of prostaglandin E on mouse mast cell induction. J. Immunol. 155: 2134-2142.
48. 2 selectively enhances the IgE-mediated production of IL-6 and granulocyte-macrophage colonystimulating factor by mast cells through an EP1/EP3-dependent mechanism. J. Immunol. 165: 6545-6552.
49. 2 induces degranulation-independent production of vascular endothelial growth factor by human mast cells. J. Immunol. 172: 1227-1236.
50. 2-induced inhibition of interleukin 2 production. J. Immunol. 130: 1770-1773.
51. 2 and the increase of intracellular cAMP inhibit the expression of interleukin 2 receptors in human T cells. Eur. J. Immunol. 18: 1791-1796.
52. 2, promote type 2 cytokine production in maturing human naive T helper cells. J. Immunol. 159: 28-35.
53. Sharma, S., M. Stolina, S. C. Yang, F. Baratelli, J. F. Lin, K. Atianzar, J. Luo, L. Zhu, Y. Lin, M. Huang, et al. 2003. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin. Cancer Res. 9: 961-968. (Pubitemid 36323698)
54. Sombroek, C. C., A. G. Stam, A. J. Masterson, S. M. Lougheed, M. J. Schakel, C. J. Meijer, H. M. Pinedo, A. J. van den Eertwegh, R. J. Scheper, and T. D. de Gruijl. 2002. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol. 168: 4333-4343. (Pubitemid 34441333)
55. + Th1 cells. J. Immunol. 187: 1157-1165.
56. Lim, H. W., G. J. Thorbecke, R. L. Baer, and I. Gigli. 1983. Effect of indomethacin on alteration of ATPase-positive Langerhans cell density and cutaneous sunburn reaction induced by ultraviolet-B radiation. J. Invest. Dermatol. 81: 455-458. (Pubitemid 14228078)
57. + cells via an indomethacin-inhibitable pathway. J. Immunol. 185: 7207-7215.
58. 2 and COX2 redirects the differentiation of human dendritic cells towards stable myeloid-derived suppressor cells. Blood. 118: 5498-5505.
59. Jonuleit, H., U. Kühn, G. Müller, K. Steinbrink, L. Paragnik, E. Schmitt, J. Knop, and A. H. Enk. 1997. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27: 3135-3142. (Pubitemid 28018007)
60. 2 and tumor necrosis factor α cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production. J. Exp. Med. 186: 1603-1608.
61. + dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J. Immunol. 161: 2804-2809.
62. 2 regulates the migratory capacity of specific DC subsets. Blood 100: 1362-1372.
63. 2 is a key factor for CCR7 surface expression and migration of monocytederived dendritic cells. Blood 100: 1354-1361.
64. 2 in podosome dissolution and induction of high-speed migration during dendritic cell maturation. J. Immunol. 177: 1567-1574.
65. 2-induced metalloproteinase- 9 is essential for dendritic cell migration. Blood 111: 260-270.
66. 2 transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells. Blood 116: 1454-1459.
67. 2- dependent enhancement of tissue inhibitors of metalloproteinases-1 production limits dendritic cell migration through extracellular matrix. J. Immunol. 173: 5458-5466.
68. De Vries, I. J., D. J. Krooshoop, N. M. Scharenborg, W. J. Lesterhuis, J. H. Diepstra, G. N. Van Muijen, S. P. Strijk, T. J. Ruers, O. C. Boerman, W. J. Oyen, et al. 2003. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 63: 12-17. (Pubitemid 36070411)
69. Quillien, V., A. Moisan, A. Carsin, T. Lesimple, C. Lefeuvre, H. Adamski, N. Bertho, A. Devillers, C. Leberre, and L. Toujas. 2005. Biodistribution of radiolabelled human dendritic cells injected by various routes. Eur. J. Nucl. Med. Mol. Imaging 32: 731-741. (Pubitemid 41125414)
70. 2 production in murine dendritic cells and alters the cytokine profile, but does not affect maturation or migration. Prostaglandins Leukot. Essent. Fatty Acids 84: 113-121.
71. Doyen, V., M. Rubio, D. Braun, T. Nakajima, J. Abe, H. Saito, G. Delespesse, and M. Sarfati. 2003. Thrombospondin 1 is an autocrine negative regulator of human dendritic cell activation. J. Exp. Med. 198: 1277-1283. (Pubitemid 37323392)
72. Braun, D., R. S. Longman, and M. L. Albert. 2005. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 106: 2375-2381. (Pubitemid 41510810)
73. Kaliński, P., C. M. Hilkens, E. A. Wierenga, and M. L. Kapsenberg. 1999. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol. Today 20: 561-567.
74. Gustafsson, K., M. Ingelsten, L. Bergqvist, J. Nyström, B. Andersson, and A. Karlsson-Parra. 2008. Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine. Cancer Res. 68: 5965-5971.
75. Hokey, D. A., A. T. Larregina, G. Erdos, S. C. Watkins, and L. D. Falo, Jr. 2005. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity. Cancer Res. 65: 10059-10067. (Pubitemid 41541488)
76. Mailliard, R. B., A. Wankowicz-Kalinska, Q. Cai, A. Wesa, C. M. Hilkens, M. L. Kapsenberg, J. M. Kirkwood, W. J. Storkus, and P. Kalinski. 2004. Alphatype- 1 polarized dendritic cells: a novel immunization tool with optimized CTLinducing activity. Cancer Res. 64: 5934-5937. (Pubitemid 39129387)
77. Campbell, D. J., C. H. Kim, and E. C. Butcher. 2003. Chemokines in the systemic organization of immunity. Immunol. Rev. 195: 58-71. (Pubitemid 37153453)
78. 2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. Blood 102: 1966-1977.
79. 2 and other cyclic adenosine monophosphateelevating agents: impact on interleukin-2 receptor signaling pathway. Blood 93: 2308-2318.
80. Hahn, T., I. Alvarez, J. J. Kobie, L. Ramanathapuram, S. Dial, A. Fulton, D. Besselsen, E. Walker, and E. T. Akporiaye. 2006. Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer. Int. J. Cancer 118: 2220-2231.
81. Haas, A. R., J. Sun, A. Vachani, A. F. Wallace, M. Silverberg, V. Kapoor, and S. M. Albelda. 2006. Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin. Cancer Res. 12: 214-222. (Pubitemid 43166197)
82. 2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J. Immunol. 146: 108-113.
83. 2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J. Immunol. 150: 5321-5329.
84. 2 is a potent inhibitor of human interleukin 12 production. J. Exp. Med. 181: 775-779.
85. 2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness. J. Immunol. 161: 2723-2730.
86. 2 is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood 97: 3466-3469.
87. Whittaker, D. S., K. S. Bahjat, L. L. Moldawer, and M. J. Clare-Salzler. 2000. Autoregulation of human monocyte-derived dendritic cell maturation and IL-12 production by cyclooxygenase-2-mediated prostanoid production. J. Immunol. 165: 4298-4304.
88. Gillessen, S., D. Carvajal, P. Ling, F. J. Podlaski, D. L. Stremlo, P. C. Familletti, U. Gubler, D. H. Presky, A. S. Stern, and M. K. Gately. 1995. Mouse interleukin- 12 (IL-12) p40 homodimer: a potent IL-12 antagonist. Eur. J. Immunol. 25: 200-206.
89. Kapsenberg, M. L., C. M. Hilkens, E. A. Wierenga, and P. Kalinski. 1999. The paradigm of type 1 and type 2 antigen-presenting cells: implications for atopic allergy. Clin. Exp. Allergy 29(Suppl. 2): 33-36. (Pubitemid 29314660)
90. 2 in experimental inflammatory bowel disease is mediated through the IL-23→IL-17 axis. J. Immunol. 178: 8138-8147.
91. 2, which inhibits generation of γ interferon-positive T cells. Infect. Immun. 76: 2651-2659.
92. 2-EP4 signaling in mouse experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 107: 12233-12238.
93. 2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J. Exp. Med. 206: 535-548.
94. 2 alters the IL-12/IL-23 balance and promotes differentiation of Th17 cells. J. Immunol. 181: 721-735.
95. Hale, A. H., D. L. Evans, and L. W. Daniel. 1982. Effect of prostaglandins on elicitation of anti-viral-cytolytic activity. Immunol. Lett. 4: 171-174. (Pubitemid 12148396)
96. Plaut, M., G. Marone, and E. Gillespie. 1983. The role of cyclic AMP in modulating cytotoxic T lymphocytes, II: Sequential changes during culture in responsiveness of cytotoxic lymphocytes to cyclic AMP-active agents. J. Immunol. 131: 2945-2952. (Pubitemid 14207329)
97. Lala, P. K., T. G. Kennedy, and R. S. Parhar. 1988. Suppression of lymphocyte alloreactivity by early gestational human decidua, II: Characterization of the suppressor mechanisms. Cell. Immunol. 116: 411-422. (Pubitemid 18269318)
98. 2-mediated inactivation of various killer lineage cells by tumor-bearing host macrophages. J. Leukoc. Biol. 44: 474-484.
99. Specht, C., S. Bexten, E. Kölsch, and H. G. Pauels. 2001. Prostaglandins, but not tumor-derived IL-10, shut down concomitant tumor-specific CTL responses during murine plasmacytoma progression. Int. J. Cancer 91: 705-712. (Pubitemid 32115268)
100. Valitutti, S., M. Dessing, and A. Lanzavecchia. 1993. Role of cAMP in regulating cytotoxic T lymphocyte adhesion and motility. Eur. J. Immunol. 23: 790-795. (Pubitemid 23101059)
101. + T cell expansion by dendritic cells. J. Immunol. 184: 591-597.
102. Garcia-Peñarrubia, P., A. D. Bankhurst, and F. T. Koster. 1989. Prostaglandins from human T suppressor/cytotoxic cells modulate natural killer antibacterial activity. J. Exp. Med. 170: 601-606. (Pubitemid 19204287)
103. Simkin, N. J., D. F. Jelinek, and P. E. Lipsky. 1987. Inhibition of human B cell responsiveness by prostaglandin E2. J. Immunol. 138: 1074-1081. (Pubitemid 17017887)
104. Carini, C., B. N. Hudspith, and J. Brostoff. 1981. Effect of prostaglandins and cyclic nucleotides on growth and immunoglobulin secretion of two IgE myeloma cell lines. Br. J. Cancer 43: 257-260. (Pubitemid 11153355)
105. + T cells. J. Immunol. 175: 1483-1490.
106. + T regulatory cell activities in lung cancer. Cancer Res. 65: 5211-5220.
107. Bergmann, C., L. Strauss, R. Zeidler, S. Lang, and T. L. Whiteside. 2007. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res. 67: 8865-8873. (Pubitemid 47437463)
108. 2- prostaglandin E receptor subtype 4 (EP4) signaling mediates UV irradiationinduced systemic immunosuppression. Proc. Natl. Acad. Sci. USA 108: 6668-6673.
109. Muthuswamy, R., J. Urban, J. J. Lee, T. A. Reinhart, D. Bartlett, and P. Kalinski. 2008. Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res. 68: 5972-5978.
110. Banerjee, D. K., M. V. Dhodapkar, E. Matayeva, R. M. Steinman, and K. M. Dhodapkar. 2006. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 108: 2655-2661.
111. 2-dependent mechanism. J. Immunol. 177: 246-254.
112. Huang, M., M. Stolina, S. Sharma, J. T. Mao, L. Zhu, P. W. Miller, J. Wollman, H. Herschman, and S. M. Dubinett. 1998. Non-small cell lung cancer cyclooxygenase- 2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res. 58: 1208-1216. (Pubitemid 28183210)
113. Stolina, M., S. Sharma, Y. Lin, M. Dohadwala, B. Gardner, J. Luo, L. Zhu, M. Kronenberg, P. W. Miller, J. Portanova, et al. 2000. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol. 164: 361-370. (Pubitemid 30013010)
114. Ochoa, A. C., A. H. Zea, C. Hernandez, and P. C. Rodriguez. 2007. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin. Cancer Res. 13: 721s-726s.
115. 2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 67: 4507-4513.
116. Fujita, M., G. Kohanbash, W. Fellows-Mayle, R. L. Hamilton, Y. Komohara, S. A. Decker, J. R. Ohlfest, and H. Okada. 2011. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res. 71: 2664-2674.
117. Serafini, P. 2010. Editorial: PGE2-producing MDSC: a role in tumor progression? J. Leukoc. Biol. 88: 827-829.
118. Jung, Y. J., J. S. Isaacs, S. Lee, J. Trepel, and L. Neckers. 2003. IL-1beta-mediated up-regulation of HIF-1α via an NFκB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 17: 2115-2117.
119. Corzo, C. A., T. Condamine, L. Lu, M. J. Cotter, J. I. Youn, P. Cheng, H. I. Cho, E. Celis, D. G. Quiceno, T. Padhya, et al. 2010. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 207: 2439-2453.
120. Freire-de-Lima, C. G., D. O. Nascimento, M. B. Soares, P. T. Bozza, H. C. Castro-Faria-Neto, F. G. de Mello, G. A. DosReis, and M. F. Lopes. 2000. Uptake of apoptotic cells drives the growth of a pathogenic trypanosome in macrophages. Nature 403: 199-203.
121. Mittal, R., I. Gonzalez-Gomez, A. Panigrahy, K. Goth, R. Bonnet, and N. V. Prasadarao. 2010. IL-10 administration reduces PGE-2 levels and promotes CR3-mediated clearance of Escherichia coli K1 by phagocytes in meningitis. J. Exp. Med. 207: 1307-1319.
122. 2 inhibits monocyte function by interfering with CCR5 and Mac-1. FASEB J. 14: 661-668.
123. 2 on NKDC interaction are imprinted during dendritic cell maturation. Blood 118: 2473-2482.
124. McIlroy, A., G. Caron, S. Blanchard, I. Frémaux, D. Duluc, Y. Delneste, A. Chevailler, and P. Jeannin. 2006. Histamine and prostaglandin E up-regulate the production of Th2-attracting chemokines (CCL17 and CCL22) and downregulate IFN-γ-induced CXCL10 production by immature human dendritic cells. Immunology 117: 507-516.
125. Obermajer, N., R. Muthuswamy, K. O. Odunsi, R. P. Edwards, and P. Kalinski. 2011. PGE2-dependent CXCL12 production and CXCR4 expression control the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. DOI: 10.1158/0008-5472.CAN-11-2449.
126. Stock, A., S. Booth, and V. Cerundolo. 2011. Prostaglandin E2 suppresses the differentiation of retinoic acid-producing dendritic cells in mice and humans. J. Exp. Med. 208: 761-773.
127. Oppenheimer-Marks, N., A. F. Kavanaugh, and P. E. Lipsky. 1994. Inhibition of the transendothelial migration of human T lymphocytes by prostaglandin E2. J. Immunol. 152: 5703-5713. (Pubitemid 24174149)
128. 2 and monoclonal antibody to lymphocyte function-associated antigen-1 differentially inhibit migration of T lymphocytes across microvascular retinal endothelial cells in rat. Immunology 88: 471-477.
129. Vancheri, C., C. Mastruzzo, M. A. Sortino, and N. Crimi. 2004. The lung as a privileged site for the beneficial actions of PGE2. Trends Immunol. 25: 40-46 (Pubitemid 38032806)